drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An intravenous chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-α, blocking TNFR1/2 signaling and NF-κB–driven inflammation; can induce apoptosis of activated T cells/monocytes and promote mucosal healing. Regimen: 10 mg/kg at week 0, then 5 mg/kg at weeks 2, 4, and 8; maintenance every 6 weeks from week 12.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-α, neutralizing TNF and preventing engagement of TNFR1/2. This blocks downstream NF-κB–driven inflammatory signaling, reduces proinflammatory cytokines and adhesion molecule expression, and can trigger apoptosis of activated T cells/monocytes, promoting mucosal healing.
drug_name
Infliximab
nct_id_drug_ref
NCT05552287